{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Objective response rate was defined as the number of subjects achieving a complete response (CR) or partial response (PR) after at least four cycles of ixazomib (MLN9708) and bendamustine plus dexamethasone.","groups":[{"description":"Ixazomib 4 mg, days 1, 8, 15.\n\nDexamethasone 40 mg oral weekly.\n\nBendamustine dose levels: 80mg/m2 days 1,2\n\nMLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.\n\nDexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.\n\nBendamustine: 80mg/m2 days 1,2","id":"OG000","title":"MLN9708, Bendamustine and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Subjects receiving the fixed dose of 80 mg/m\\^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m\\^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}